Symmetry Partners LLC Cuts Stock Holdings in Stryker Corporation $SYK

Symmetry Partners LLC decreased its position in shares of Stryker Corporation (NYSE:SYK) by 1.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,675 shares of the medical technology company’s stock after selling 28 shares during the quarter. Symmetry Partners LLC’s holdings in Stryker were worth $662,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the company. Brighton Jones LLC lifted its position in Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after purchasing an additional 609 shares during the period. Centaurus Financial Inc. lifted its position in Stryker by 16.8% during the fourth quarter. Centaurus Financial Inc. now owns 1,246 shares of the medical technology company’s stock valued at $449,000 after purchasing an additional 179 shares during the period. Moody National Bank Trust Division bought a new position in Stryker during the first quarter valued at approximately $212,000. BTC Capital Management Inc. lifted its position in Stryker by 6.7% during the first quarter. BTC Capital Management Inc. now owns 2,741 shares of the medical technology company’s stock valued at $1,020,000 after purchasing an additional 171 shares during the period. Finally, Beese Fulmer Investment Management Inc. raised its position in Stryker by 0.6% in the first quarter. Beese Fulmer Investment Management Inc. now owns 42,663 shares of the medical technology company’s stock worth $15,881,000 after acquiring an additional 246 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Stryker Stock Performance

SYK opened at $368.83 on Friday. The stock has a market capitalization of $141.01 billion, a price-to-earnings ratio of 48.85, a PEG ratio of 2.66 and a beta of 0.93. The company has a fifty day moving average of $385.71 and a 200 day moving average of $379.08. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating the consensus estimate of $3.07 by $0.06. The company had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. Stryker’s quarterly revenue was up 11.1% on a year-over-year basis. During the same period last year, the company posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, sell-side analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 44.50%.

Analyst Ratings Changes

Several research firms have weighed in on SYK. Redburn Partners set a $420.00 price target on shares of Stryker in a research report on Thursday, September 18th. Wells Fargo & Company increased their price target on shares of Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Evercore ISI increased their price target on shares of Stryker from $390.00 to $415.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 8th. BTIG Research reiterated a “buy” rating on shares of Stryker in a research report on Monday, July 14th. Finally, Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research report on Friday. Fourteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $430.33.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.